Work

Abstract GS1-03: Adjuvant aromatase inhibitor or tamoxifen in patients with hormone receptor-positive/HER2-positive early breast cancer: An exploratory analysis from the ALTTO (BIG 2-06) trial

Year: 2026

Type: conference-abstract

Source: Clinical Cancer Research

DOI: 10.1158/1557-3265.sabcs25-gs1-03

Authors: M. Lambertini, F. Samy, E. Agostinetto, L. Arecco, P. Freire, A. Sonnenblick, G. Arpino, L. Del Mastro, A. Choudhury, N. Harbeck, I. Vaz-Luis, V. Kaklamani, A. Wolff, A. Partridge, S. Loi, S. Fielding, M. Piccart, S. Di Cosimo, E. de Azambuja

Institutions: Ospedale Policlinico San Martino, Université Libre de Bruxelles, Institut Jules Bordet, Hospital de Câncer de Pernambuco, Tel Aviv University, Tel Aviv Sourasky Medical Center, Federico II University Hospital, University of Naples Federico II, Novartis (India), LMU Klinikum, Ludwig-Maximilians-Universität München, Institut Gustave Roussy, Johns Hopkins University, Johns Hopkins Medicine, Harvard University, Dana-Farber Cancer Institute, Peter MacCallum Cancer Centre, Fondazione IRCCS Istituto Nazionale dei Tumori

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7129251379

Cites:

Cited by: 5

Related to: